Halozyme Therapeutics, Inc. (HALO) Stock Price & Analysis

Halozyme Therapeutics, Inc. (HALO) rose 1.06% to USD 71.48 as of June 10, 2026 at 00:52 UTC, according to Nexqual real-time market data.

HALO last closed at USD 70.73; the session ranged USD 70.24–72.29 on volume of 1,317,356 shares. Market capitalization is $8.48B, with a 52-week range of USD 51.06–82.22 (NMS). Source: Nexqual, June 10, 2026 at 00:52 UTC.

Key Statistics (as of June 10, 2026 at 00:52 UTC)

Technical Analysis (HALO)

Nexqual's technical model rates HALO "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:52 UTC.

Analyst Ratings (HALO)

Wall Street analysts rate HALO "Buy" based on 10 analysts, with a mean price target of USD 83.9 (range USD 57–96), per Nexqual as of June 10, 2026 at 00:52 UTC.

Earnings (HALO)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:52 UTC.

Financials & Fundamentals (HALO)

Source: Nexqual, June 10, 2026 at 00:52 UTC.

Financial Health Score (HALO)

Nexqual rates Halozyme Therapeutics, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:52 UTC.

Ownership (HALO)

Source: Nexqual, June 10, 2026 at 00:52 UTC.

Leadership (HALO)

Halozyme Therapeutics, Inc. is led by Helen I. Torley M.B. Ch. B., M.R.C.P. (age 62), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:52 UTC.

Major Backers & Investors (HALO)

Notable institutional backers of Halozyme Therapeutics, Inc. include Invesco, Bank of America Corporation, Boston Partners, according to Nexqual as of June 10, 2026 at 00:52 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:52 UTC.

From Halozyme Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)

Key Strengths & Strategy (as disclosed to the SEC)

• We will also continue our efforts to enter into new collaborations to derive additional revenue from our proprietary technology.
• In April 2023, Takeda announced the FDA approved the supplemental Biologics License Application to expand the use of HYQVIA to treat Primary Immunodeficiency in children.
• Teva's Epinephrine Injection, utilizing our patented VIBEX ® injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to the branded products EpiPen ® and EpiPen Jr ® and therefore, subject to state law, substitutable at the pharmacy.
• For our products and product candidates, we verify that they are manufactured in accordance with FDA's current Good Manufacturing Practices for drug products and the FDA's current Quality System Regulations for medical devices and equivalent provisions in the EU and elsewhere, which are required as part of the overall obligations necessary, in the EU for instance, to obtain a CE-mark.

Partnerships

• Device and Other Drug Product Collaborations Teva License, Development and Supply Agreements In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada.
• In December 2025, we entered into a commercial license and supply agreement with Viatris under which we license and supply an auto-injector product for self-administered SC selatogrel for the treatment of acute myocardial infarction in adult patients. 17 Table of Contents Patents and Intellectual Proprietary Rights Patents and other intellectual proprietary rights are essential to our business.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:52 UTC. This page is informational and not investment advice.